SUPN Supernus Pharmaceuticals, Inc. Net Financial Result

Official company branding of Supernus (SUPN)

Supernus Pharmaceuticals (SUPN) is effectively scaling its biopharmaceutical business, converting scientific research into global profits. The company's financial profit demonstrates fundamental resilience, with the value holding at -0.04. Stability is ensured by patent-driven pricing power within the CNS segment. Additional profit growth is driven by the implementation of robotic filling and blending lines, minimizing production costs.

Supernus Pharmaceuticals, Inc. (SUPN) Company Net Income: for the period 07/04/2022 - 10/31/2026

Analytical breakdowns and data insights for company Supernus (SUPN)

- stock value and consensus price forecast:
Market Price Supernus Corp|SUPN - Price Target Chart
- market capitalization data:
Market Capitalization Supernus Corp|SUPN - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Supernus|SUPN - Company Book Value|Market Capitalization to Net Assets supernus.com|SUPN - Company Total Assets
- debt and solvency information:
Debt to Capital Supernus Pharmaceuticals|SUPN - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Supernus Pharmaceuticals, Inc.|SUPN - Company Debts|Debt to Book Value Ratio Supernus Corp|SUPN - Company Long-Term Liabilities|Company Short-Term Debts Supernus|Interim Coverage Ratio supernus.com
- earnings and market multiples details:
SUPN - Net Income
Basic company analysis:Supernus Corp
Signature product of Supernus Pharmaceuticals, Inc.

This indicator accumulates the daily volume of actual earnings, allowing investors to assess business sustainability and the security of future dividends through trend analysis. The integration of ESG standards and the ethics of CNS drug development minimize operational risks, which is confirmed by the stability of the company's cash profit and guarantees the fundamental strength of the market positions of Supernus Pharmaceuticals (SUPN).

Key competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|regencellbioscience.com (RGC) - Net Financial Result|Net Income AXSM (Axsome Therapeutics, Inc.)|Net Profit ACADIA Pharma (ACAD)|Company Net Income Xenon Pharmaceuticals Inc XENE|VKTX (Viking Therapeutics Corp) - Profit After Tax|Catalyst Pharmaceuticals - Net Profit|Company Net Income denalitherapeutics.com|Harmony Biosciences Holdings, Inc. (HRMY) - Company Net Income|Biohaven Ltd - Final Profit|Company Net Income Amylyx|Company Profit TRVI (Trevi Corp)|Net Income PRAX (Praxis Precision Medicines)|Net Profit anavex.com (AVXL)|Company Net Income CeriBell CBLL|Net Financial Result Prothena Corp (PRTA)|ALEC: Net Income|Final Profit ANNX (Annexon Biosciences Inc.)|omeros.com (OMER) - Company Net Income|Profit After Tax NGNE (neurogene.com)|ACIU (AC Immune SA) - Net Profit|VYGR: Final Profit|Net Profit NMRA|Net Profit Scilex Holding Company, Inc. (SCLX)|Company Net Income Tevogen Bio Holdings TVGN|Final Profit ACOG|CGTX - Company Net Income|Inhibikase Therapeutics Inc (IKT) - Net Income|SAVA: Net Profit|Assertio (ASRT) - Net Profit|COYA (Coya Therapeutics Inc) - Net Profit|Net Income VistaGen Therapeutics Inc (VTGN)|Net Profit OVID|ABOS - Company Net Income|CervoMed Inc - Net Income|Net Profit Alterity Therapeutics Ltd. ATHE|CLNN: Net Income|PepGen Inc. - Profit After Payment of Taxes|JUNS: Net Profit|RLMD - Net Financial Result|ANVS (Annovis Bio Corp) - Net Profit|Net Income Grace Tx (GRCE)|Net Profit AIFF|Net Profit anewmeds.com (KLTO)|Company Net Income NeuroSense Therapeutics Ltd. NRSN|Reviva Pharmaceuticals Holdings Inc. - Company Net Income|MTVA - Company Net Income|Net Financial Result NeurAxis Inc NRXS|heliusmedical.com (HSDT) - Company Net Income|PASG - Net Financial Result|Net Income NEUP|Net Profit Minerva Neurosciences Inc|Company Net Income Athira (ATHA)|ADXN: Profit After Tax|Company Net Income Alzamend Neuro ALZN|CYCN: Company Profit|PTIX - Company Net Income|KTTA (Pasithea Therapeutics) - Company Profit|CRGT: Net Profit|Company Net Income Avenue Therapeutics Inc (ATXI)|Net Income BCLI|Net Profit caratherapeutics.com|Company Net Income Chromocell Therapeutics Corp. (CHRO)|ELYM (eliemtx.com) - Final Profit|Company Net Income Intra-Cellular Therapies, Inc. ITCI|Longboard (LBPH) - Company Net Income|MRNS - Company Net Income|Net Financial Result nkgenbiotech.com NKGN|NRBO (NeuroBo Pharmaceuticals, Inc.) - Net Income|Sage Therapeutics Inc. (SAGE) - Net Profit|Company Net Income Neurotrope|Trevena Inc - Profit After Tax|Net Profit VIGL|WENA - Company Net Income|Company Net Income Cerevel Therapeutics, Inc. CERE